ArticleAnnals of clinical and translational neurology2026
Subjective Cognitive Concerns and Cognitive Trajectories in Parkinson's Disease: Biomarker Impact.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo examine the relationship of subjective cognitive concerns (SCC) with biomarkers of Alzheimer's disease (AD), neurodegeneration, and Parkinson's disease (PD) and domain-specific cognitive trajectories among cognitively unimpaired persons with de novo PD.
methodCognitively unimpaired participants with SCC (n = 294) and without SCC (n = 857) from the Parkinson's Progression Markers Initiative underwent neuropsychological testing, lumbar puncture, and dopamine transporter (DaT) single-photon emission computed tomography (SPECT). Multiple regression analyses examined SCC associations with biomarkers of AD (CSF phosphorylated-tau181/amyloid-beta42 [p-tau181/Aβ42]), neurodegeneration (CSF neurofilament light [NfL]), and PD (DaT-SPECT in contralateral putamen). Linear mixed effects models examined 5-year cognitive trajectories (working memory, category fluency, learning and memory, visuospatial functioning, processing speed) by SCC status and the extent to which biomarkers of AD, neurodegeneration, and PD moderated these associations.
resultAt baseline, the SCC group had higher p-tau181/Aβ42 (FDR-adjusted p = 0.004) than the No SCC group, while NfL and DaT-SPECT did not differ. Relative to the No SCC group, the SCC group exhibited faster decline in learning (FDR-adjusted p = 0.016), delayed recall (FDR-adjusted p = 0.016) and working memory (FDR-adjusted p = 0.016). AD and PD-related biomarkers moderated cognitive trajectories: SCC in combination with (1) higher CSF p-tau181/Aβ42 was related to steeper declines in working memory (FDR-adjusted p = 0.032); and (2) lower DaT-SPECT was related to steeper declines in delayed recall (FDR-adjusted p = 0.032).
interpretationSCC is related to AD biomarkers and accelerated cognitive decline in the earliest stages of PD. SCC may serve as an early marker of cognitive risk, especially among persons with greater AD- or PD-related burden.
Indexed as
Identifiers
42847555What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.